A Study of Baricitinib in Participants With Rheumatoid Arthritis

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Eli Lilly and Company
Updated on 22 September 2021
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Primary Contact
Greater Chicago Specialty Physicians, LLC (9.1 mi away) Contact
+170 other location
body mass index
tumor necrosis factor
tumor necrosis factor alpha
tumour necrosis


This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).

Condition Rheumatoid Arthritis, Rheumatoid Arthritis (Pediatric)
Treatment Baricitinib, TNF Inhibitor
Clinical Study IdentifierNCT04086745
SponsorEli Lilly and Company
Last Modified on22 September 2021


Yes No Not Sure

Inclusion Criteria

Participants must have at least one of the following characteristics
Documented evidence of a VTE prior to this study
At least 60 years of age
A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m), or
Age 50 to less than 60 years and BMI 25 to less than 30 kg/m
Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic)

Exclusion Criteria

Participant must not have prior use of a Janus kinase (JAK) inhibitor or have received more than 1 prior TNF inhibitor that was
discontinued for IR (lack or loss of efficacy) for RA, or
discontinued for intolerance (AE) when used for any indication
Participants must not be pregnant or breastfeeding
Participants must not have had more than one VTE
Participants must not have cancer
Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness
Participants must not have had a live vaccine within four weeks of study start
Participants must not have participated in any other clinical trial within four weeks of study start
Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note